FLOW Trial: Semaglutide Reduces Kidney Disease Progression by 24%
GLP-1 Authority Editorial Team
Medical News Desk
The FLOW trial demonstrated that semaglutide significantly reduced the risk of major kidney disease events in patients with type 2 diabetes and chronic kidney disease, expanding the drug's clinical utility.
Key Points
- 24% reduction in major kidney disease events with semaglutide vs. placebo
- 3,533 patients with type 2 diabetes and chronic kidney disease enrolled across 28 countries
- Trial stopped early due to overwhelming efficacy — a rare occurrence in nephrology
- Semaglutide reduced kidney failure, dialysis initiation, and kidney-related death
- FDA is reviewing a supplemental application for a chronic kidney disease indication
The FLOW Trial: Background
The FLOW (Evaluate Renal Function with Semaglutide Once Weekly) trial was a Phase 3 randomized controlled trial designed to evaluate whether semaglutide 1mg weekly could reduce the progression of chronic kidney disease (CKD) in patients with type 2 diabetes. CKD affects approximately 40% of patients with type 2 diabetes and is a leading cause of kidney failure, dialysis, and premature death. Prior to FLOW, no GLP-1 receptor agonist had been specifically approved for CKD.
Trial Design
FLOW enrolled 3,533 adults with type 2 diabetes and CKD across 28 countries. Participants were randomized 1:1 to semaglutide 1mg weekly or placebo, in addition to standard of care including renin-angiotensin system blockade. The primary endpoint was a composite of kidney failure (dialysis, transplant, or sustained eGFR below 15), sustained 50% or more eGFR decline, or kidney or cardiovascular death.
Early Termination Due to Efficacy
The FLOW trial was stopped early by the independent data monitoring committee after a pre-specified interim analysis demonstrated overwhelming efficacy. Early termination due to efficacy is rare in nephrology trials and underscores the magnitude of the benefit. The trial had been planned to run for approximately 4 years; it was stopped after a median follow-up of 3.4 years.
Primary Results
Semaglutide reduced the primary composite endpoint by 24% compared to placebo (HR 0.76; 95% CI 0.66 to 0.88). This translates to a number needed to treat of approximately 20 over 3 years to prevent one major kidney event. Individual components of the composite were also reduced: kidney failure by 20%, sustained 50% or more eGFR decline by 31%, and kidney or cardiovascular death by 19%.
Mechanism of Kidney Protection
The mechanisms by which semaglutide protects the kidneys are not fully understood but likely involve multiple pathways. GLP-1 receptors are expressed in the kidney, and GLP-1 agonists have been shown to reduce glomerular hyperfiltration, decrease albuminuria, and reduce renal inflammation and fibrosis in animal models. Additionally, semaglutide's systemic effects — including blood pressure reduction, weight loss, and improved glycemic control — may contribute to kidney protection.
Regulatory Implications
The manufacturer has submitted a supplemental New Drug Application to the FDA seeking approval of semaglutide for the treatment of CKD in patients with type 2 diabetes. If approved, this would make semaglutide the first GLP-1 receptor agonist with a specific CKD indication, joining SGLT2 inhibitors as a cornerstone of CKD management in type 2 diabetes. A decision is expected by late 2026.
Clinical Implications for Patients
For patients with type 2 diabetes and CKD, the FLOW results provide compelling evidence to discuss semaglutide with their nephrologist or endocrinologist. Current guidelines already recommend GLP-1 agonists for patients with type 2 diabetes and CKD based on cardiovascular outcome data; FLOW now adds direct kidney protection evidence. Patients with advanced CKD or on dialysis were not included in FLOW and should discuss GLP-1 therapy with their specialist.
Medical Disclaimer: This article is for informational and educational purposes only and does not constitute medical advice. Always consult a licensed healthcare provider before starting, stopping, or changing any medication.